DOCSLIB.ORG

Minims® Chloramphenicol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Minims® Chloramphenicol Minims® Chloramphenicol Eye Drops Chloramphenicol Eye Drops Consumer Medicine Information What is in this leaflet glued eyes, especially in the morning under 2 years of age unless your on waking). Other symptoms include doctor tells you. This leaflet answers some common a gritty sensation in the eye, redness, Do not use this medicine after the questions about Minims irritation and watering of the eyes. expiry date printed on the pack or Chloramphenicol, including how to The infection usually starts in one if the packaging is torn or shows use the eye drops. eye and then spreads to the other. signs of tampering. It does not contain all the available Ask your doctor, pharmacist or If it has expired or is damaged, return information. It does not take the optometrist if you have any it to your pharmacist for disposal. place of talking to your doctor or questions about why this medicine has been prescribed for you. They If you are not sure whether you pharmacist. should start using this medicine, may have prescribed it for another All medicines have benefits and talk to your doctor. reason. risks. Your pharmacist , doctor or optometrist has weighed the risks of Before you start to use it you using Minims Chloramphenicol Tell your pharmacist, doctor or against the benefits they expect it optometrist if the following will have for you. Before you use Minims conditions apply: If you have any concerns about Chloramphenicol • if you have had an allergy to using this medicine, ask your any other medicines, foods, doctor or pharmacist. When you must not use it preservatives or dyes. Keep this leaflet with the medicine. Do not use Minims • if you have any blood disorder You may need to read it again. Chloramphenicol if you have an such as reduced blood cells, or allergy to: lack of white blood cells or low blood platelet count. • Any medicine containing chloramphenicol Your pharmacist, doctor or What Minims optometrist may wish to use an • Chloramphenicol is Any of the ingredients listed at alternative treatment since the end of this leaflet. used for chloramphenicol has been Some of the symptoms of an allergic associated with depression of the Minims Chloramphenicol is a broad- reaction may include: bone marrow, which is a serious spectrum antibiotic solution that is • Shortness of breath complaint. used to treat an eye infection called • if you are to have or have had bacterial conjunctivitis, which is a • Wheezing or difficulty breathing eye surgery bacterial infection involving the • Swelling of the face, lips, tongue mucous membrane of the surface of or other parts of the body Your pharmacist, doctor or the eye. optometrist may wish to use an • Rash, itching or hives on the skin alternative treatment since The most common symptom is the Do not use Minims chloramphenicol may slow presence of a sticky yellow-white Chloramphenicol on children corneal wound healing discharge with mucus and pus (or MINIMS® CHLORAMPHENICOL 1 • if you are pregnant or plan to • your eye looks cloudy medicines, or you may need to use become pregnant. • there is copious yellow-green different medicines. Your doctor will advise you of purulent discharge that Your doctor and pharmacist will the risks and benefits involved. accumulates after being wiped have more information on medicines • if you are breast-feeding or away to be careful with or avoid while intend to breast-feed. • you have injured your eye or using this medicine. Your doctor will discuss the risks there is a foreign body in the eye and benefits involved. • you have been welding without • if you wear contact lenses. eye protection immediately before your eye symptoms How to use Minims Contact lenses should not be appeared Chloramphenicol worn during the course of Minims Chloramphenicol treatment. If • you have glaucoma Follow all directions given to you you wear hard or disposable • you have dry eye syndrome by your doctor or pharmacist carefully. contact lenses, you can start using • you have had similar symptoms them again after successfully in the past They may differ from the completing the course of • information contained in this leaflet. treatment. If wearing soft contact you have had eye surgery or laser treatment in the past six months If you do not understand the lenses, you should wait 24 hours instructions on the label, ask your after successfully completing a • you have recently travelled doctor or pharmacist for help. course of treatment before overseas starting to use them again. • you have surgery (including How much to use If you have not told your dental surgery) using a general pharmacist, doctor or optometrist anaesthetic Use Minims Chloramphenicol only when prescribed by your about any of the above, tell • you feel unwell him/her before you start using pharmacist, doctor or optometrist. • you have any other medical Minims Chloramphenicol. The dose of the eye drops may be conditions different for each person and their If you have bought this medicine If you have not told your medical condition. Your without a prescription and without pharmacist, doctor or optometrist pharmacist, doctor or optometrist prior consultation from a about any of the above, tell them will tell you how often to use the pharmacist, doctor or optometrist, before you use Minims eye drops and how many drops to it is important to check the Chloramphenicol. use each time. following list. Speak to your pharmacist, doctor or optometrist The usual dose of Minims Taking other medicines if any of the following applies to Chloramphenicol in adults and you before you start using Minims Tell your pharmacist, doctor or children 2 years and over is one or Chloramphenicol: optometrist if you are taking any two drops instilled into each affected eye every two to six hours for two to • you are allergic to any other other medicines, including any that three days. The interval between antibiotic eye drops you buy without a prescription from your pharmacy, supermarket applications may then be increased. • you are using other eye drops or or health food shop. Severe infections may require one or ointments two drops every fifteen to twenty Some medicines and Minims • you have pain within your eye minutes to begin with then gradually Chloramphenicol may interfere with (rather than just feeling sore or reducing the frequency of application each other. These include medicines as the infection is controlled. gritty) containing: Continue treatment for at least 48 • swelling around the eye • chymotrypsin. hours after the eye appears normal. • blurred vision or sensitivity to It is not recommended to use Do not use for more than 5 days in light these eye drops at the same time total except on medical advice. If the • limited eye movement as any medicine containing condition becomes worse or does not get better after 2 days, seek medical • abnormal pupil (the black circle chymotrypsin. advice. in the centre of the eye may be These medicines may be affected by torn, not round, very big or does Minims Chloramphenicol or may Do not use in children under 2 not change size in the light) affect how well it works. You may years of age except on Doctor's need different amounts of your advice. MINIMS® CHLORAMPHENICOL 2 How to use it use your dose when you are meant If you have any irritation, pain, to. swelling, excessive tear production You may find it easier to put drops in or light-sensitivity occur while your eye while you are sitting or Otherwise, use it as soon as you using the eye drops, flush the lying down. remember, and then go back to using your medicine as you would treated eye(s) with lots of water Follow these steps to use the eye normally. (room temperature) for at least 15 drops. minutes. Do not use a double dose to make 1.Wash your hands well with soap up for the dose that you missed. Stop using the eye drops and and water. contact your doctor if these This may increase the chance of you 2.Shake the container. symptoms persist. getting an unwanted side effect. 3.Break the seal. If you wear contact lenses, stop If you are not sure what to do, ask wearing them while you are using 4.Hold the container upside down in your doctor or pharmacist. Minims Chloramphenicol. one hand between your thumb and If you have trouble using your forefinger. If you are about to be started on medicine, ask your pharmacist for any new medicine, remind your 5.Using your other hand, gently pull some hints. doctor and pharmacist that you down your lower eyelid to form a If the condition does not get better are using Minims pouch/pocket. after 2 days, seek medical advice. Chloramphenicol. 6.Tilt your head back and look up. Tell any other doctors, dentists and 7.Put the tip of the container close to pharmacists who treat you that your lower eyelid. Do not let it touch If you use too much you are using this medicine. your eye. (overdose) 8.Release one or two drops into the Things you must not do Accidental swallowing of the pouch/pocket formed between your solution is unlikely to cause any Do not stop using Minims eye and eyelid by gently squeezing bad side effects due to the low Chloramphenicol without first the container. content of Chloramphenicol. If checking with your pharmacist, 9.Close your eye. Do not blink or rub you think that an infant or young doctor or optometrist unless you your eye. child may have swallowed any or are experiencing painful sensitivity 10.While your eye is closed, place all of the contents of the container reactions such as irritation, your index finger against the inside of Minims Chloramphenicol, burning, stinging or itching.
Load more

Recommended publications
  • Therapeutic Alternatives for Drug-Resistant Cabapenemase- Producing Enterobacteria
    THERAPEUTIC ALTERNATIVES FOR MULTIDRUG-RESISTANT AND EXTREMELY All isolates resistant to carbapenems were evaluated Fig. 1: Susceptibility (%) of Carbapenemase-producing MDRE Fig. 3: Susceptibility (%) of VIM-producing MDRE to Alternative DRUG-RESISTANT CABAPENEMASE- for the presence of genes encoding carbapenemases to Alternative Antibiotics Antibiotics PRODUCING ENTEROBACTERIA OXA-48-like, KPC, GES, NDM, VIM, IMP and GIM. M. Almagro*, A. Kramer, B. Gross, S. Suerbaum, S. Schubert. Max Von Pettenkofer Institut, Faculty of Medicine. LMU Munich, München, Germany. RESULTS BACKROUND 44 isolates of CPE were collected: OXA-48 (n=29), VIM (n=9), NDM-1 (n=5), KPC (n=1) and GES (n=1). The increasing emergence and dissemination of carbapenem-resistant gram-negative bacilli has From the 44 CPE isolates, 26 isolates were identified reduced significantly the options for sufficient as Klebsiella pneumoniae (68% of the OXA-48 CPE), 8 Fig. 2: Susceptibility (%) of OXA-48-producing MDRE to Fig. 4: Susceptibility (%) of NDM-producing MDRE to Alternative antibiotic therapy. The genes encoding most of these as Escherichia coli, 6 as Enterobacter cloacae, 2 as Alternative Antibiotics Antibiotics carbapenemases reside on plasmids or transposons Citrobacter freundii,1 as Providencia stuartii and 1 as carrying additional resistance genes which confer Morganella morganii. multidrug resistance to the isolates. 31 isolates (70%) were causing an infection, including urinary tract infection (20%), respiratory tract MATERIALS AND METHODS infection (18%), abdominal infection (18%), bacteraemia (9%) and skin and soft tissue infection In the present study, we tested the in vitro activity of (5%). 13 isolates were believed to be colonizers. antimicrobial agents against a well-characterized c o l l e c t i o n o f c a r b a p e n e m a s e - p r o d u c i n g Isolates were classified as 32 MDRE and 13 XDRE.
    [Show full text]
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Spectroscopic Characterization of Chloramphenicol and Tetracycline
    A tica nal eu yt c ic a a m A r a c t Trivedi et al., Pharm Anal Acta 2015, 6:7 h a P DOI: 10.4172/2153-2435.1000395 ISSN: 2153-2435 Pharmaceutica Analytica Acta Research Article Open Access Spectroscopic Characterization of Chloramphenicol and Tetracycline: An Impact of Biofield Treatment Mahendra Kumar Trivedi1, Shrikant Patil1, Harish Shettigar1, Khemraj Bairwa2 and Snehasis Jana2* 1Trivedi Global Inc., 10624 S Eastern Avenue Suite A-969, Henderson, NV 89052, USA 2Trivedi Science Research Laboratory Pvt. Ltd., Hall-A, Chinar Mega Mall, Chinar Fortune City, Hoshangabad Rd., Bhopal- 462026, Madhya Pradesh, India Abstract Objective: Chloramphenicol and tetracycline are broad-spectrum antibiotics and widely used against variety of microbial infections. Nowadays, several microbes have acquired resistance to chloramphenicol and tetracycline. The present study was aimed to evaluate the impact of biofield treatment for spectroscopic characterization of chloramphenicol and tetracycline using FT-IR and UV-Vis spectroscopy. Methods: The study was performed in two groups (control and treatment) of each antibiotic. The control groups remained as untreated, and biofield treatment was given to treatment groups. Results: FT-IR spectrum of treated chloramphenicol exhibited the decrease in wavenumber of NO2 from 1521 cm-1 to 1512 cm-1 and increase in wavenumber of C=O from 1681 cm-1 to 1694 cm-1 in acylamino group. It may be due to increase of conjugation effect in NO2 group, and increased force constant of C=O bond. As a result, stability of both NO2 and C=O groups might be increased in treated sample as compared to control.
    [Show full text]
  • Comparison of Thimerosal Effectiveness in the Formulation of Eye Drops Containing Neomycin Sulfate and Chloramphenicol
    International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 11, Issue 1, 2019 Original Article COMPARISON OF THIMEROSAL EFFECTIVENESS IN THE FORMULATION OF EYE DROPS CONTAINING NEOMYCIN SULFATE AND CHLORAMPHENICOL MARLINE ABDASSAH1, SRI AGUNG FITRI KUSUMA2* 1Departement of Pharmaceutics, Faculty of Pharmacy, Padjadjaran University, Sumedang, West Java, Indonesia 45363, 2Department of Biology Pharmacy, Faculty of Pharmacy, Padjadjaran University, Sumedang, West Java, Indonesia 45363 Email: [email protected] Received: 27 Sep 2018, Revised and Accepted: 19 Nov 2018 ABSTRACT Objective: This study was aimed to compare the preservative efficacy of thimerosal in eye drops formulation containing neomycin sulfate and chloramphenicol as the active agents. Methods: Determination of thimerosal concentration in combinations with chloramphenicol and neomycin sulfate was carried out using the agar diffusion method. Then the thimerosal ineffective and minimal concentration was formulated into eye drops, each with 0.5% neomycin sulfate and 0.5% chloramphenicol as the active ingredient. Evaluation of eye drops was carried out for 28 d, which included: visual observation, pH measurement, sterility, and effectiveness test. Results: Thimerosal at a minimum concentration of 0.001% remain to provide antibacterial activity against common eyes contaminants. Both eyes drops containing neomycin sulfate, and chloramphenicol resulted in clear solution, sterile, and stable in the pH and antibacterial potency,showed the efficacy of thimerosal’s role in eye drops at the lowest concentration. But, the thimerosal stability as a preservative agent was affected by the pH values of the eye drops solution. Therefore, the effectivity of thimerosal in chloramphenicol (pH 7.19-7.22) was better than neomycin sulfate (6.45- 6.60).
    [Show full text]
  • BD BBL™ Sabouraud Brain Heart Infusion Agar Slants with Chloramphenicol and Gentamicin, Pkg
    BBL™ Sabouraud Brain Heart Infusion Agar Slants with Chloramphenicol and Gentamicin 8806701 • Rev. 02 • April 2015 QUALITY CONTROL PROCEDURES I INTRODUCTION This medium is used in qualitative procedures for the selective isolation and cultivation of pathogenic fungi from clinical and nonclinical specimens. II PERFORMANCE TEST PROCEDURE 1. Inoculate representative samples with the cultures listed below. a. For B. dermatitidis and T. mentagrophytes inoculate directly using a 0.01 mL loopful of fungal broth culture. b. For C. albicans and E. coli inoculate using 0.01 mL of saline suspensions diluted to yield 103 – 104 CFUs. 2. Incubate tubes with loosened caps at 25 ± 2 °C for up to 7 days in an aerobic atmosphere. 3. Expected Results Organisms ATCC® Recovery *Blastomyces dermatitidis 56218 Fair to heavy growth *Candida albicans 10231 Fair to heavy growth *Trichophyton mentagrophytes 9533 Fair to heavy growth *Escherichia coli 25922 Inhibition (partial to complete) *Recommended organism strain for User Quality Control. III ADDITIONAL QUALITY CONTROL 1. Examine the tubes for signs of deterioration as described under “Product Deterioration.” 2. Visually examine representative tubes to assure that any existing physical defects will not interfere with use. 3. Determine the pH potentiometrically at room temperature for adherence to the specification of 6.8 ± 0.2. 4. Incubate uninoculated representative samples at 20 – 25 °C and 30 – 35 °C and examine after 7 days for microbial contamination. PRODUCT INFORMATION IV INTENDED USE This medium is used in qualitative procedures for the selective isolation and cultivation of pathogenic fungi from clinical and nonclinical specimens. V SUMMARY AND EXPLANATION Sabouraud Brain Heart Infusion Agar is based on the formulation of Gorman.1 The combination of Brain Heart Infusion Agar and Sabouraud Dextrose Agar in this medium improves the recovery of fungi compared with the recovery on either medium individually.
    [Show full text]
  • Chloramphenicol Gesting That Mitochondrial DNA Is Involved in the Pathogenesis of Secondary Leukemia
    Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Chloramphenicol gesting that mitochondrial DNA is involved in the pathogenesis of secondary leukemia. CAS No. 56-75-7 Cancer Studies in Experimental Animals Reasonably anticipated to be a human carcinogen No adequate studies of the carcinogenicity of chloramphenicol in First listed in the Tenth Report on Carcinogens (2002) experimental animals were identified. In male mice given chloram- phenicol by intraperitoneal injection in combination with busulfan OH Cl (the known human carcinogen 1,4-butanediol dimethanesulfonate), H CH N CH the incidence of lymphoma was significantly higher than in mice re- CH C Cl ceiving either busulfan or chloramphenicol alone (Robin et al. 1981). CH2 O O2N HO Properties Carcinogenicity Chloramphenicol is a naturally occurring antibiotic derivative of di- chloroacetic acid that is a white to grayish or yellowish-white fine Chloramphenicol is reasonably anticipated to be a human carcinogen, crystalline powder at room temperature. It is soluble in water and based on limited evidence of carcinogenicity from studies in humans. very soluble in methanol, ethanol, butanol, ethyl acetate, chloroform, and acetone. It is fairly soluble in ether, but insoluble in benzene, pe- Cancer Studies in Humans troleum ether, and vegetable oils (IARC 1990, HSDB 2009). It is stable Numerous case reports have shown leukemia to occur after medical under normal shipping and handling conditions (Akron 2009). The treatment for chloramphenicol-induced aplastic anemia, and three biologically active form of chloramphenicol is levorotatory (Cham- case reports have documented the occurrence of leukemia after chlor- bers 2001).
    [Show full text]
  • TETRACYCLINES and CHLORAMPHENICOL Protein Synthesis
    ANTIMICROBIALS INHIBITING PROTEIN SYNTHESIS AMINOGLYCOSIDES MACROLIDES TETRACYCLINES AND CHLORAMPHENICOL Protein synthesis Aminoglycosides 1. Aminoglycosides are group of natural and semi -synthetic antibiotics. They have polybasic amino groups linked glycosidically to two or more aminosugar like: sterptidine, 2-deoxy streptamine, glucosamine 2. Aminoglycosides which are derived from: Streptomyces genus are named with the suffix –mycin. While those which are derived from Micromonospora are named with the suffix –micin. Classification of Aminoglycosides 1. Systemic aminogycosides Streptomycin (Streptomyces griseus) Gentamicin (Micromonospora purpurea) Kanamycin (S. kanamyceticus) Tobramycin (S. tenebrarius) Amikacin (Semisynthetic derivative of Kanamycin) Sisomicin (Micromonospora inyoensis) Netilmicin (Semisynthetic derivative of Sisomicin) 2. Topical aminoglycosides Neomycin (S. fradiae) Framycetin (S. lavendulae) Pharmacology of Streptomycin NH H2N NH HO OH Streptidine OH NH H2N O O NH CHO L-Streptose CH3 OH O HO O HO NHCH3 N-Methyl-L- Glucosamine OH Streptomycin Biological Source It is a oldest aminoglycoside antibiotic obtained from Streptomyces griseus. Antibacterial spectrum 1. It is mostly active against gram negative bacteria like H. ducreyi, Brucella, Yersinia pestis, Francisella tularensis, Nocardia,etc. 2. It is also used against M.tuberculosis 3. Few strains of E.coli, V. cholerae, H. influenzae , Enterococci etc. are sensitive at higher concentration. Mechanism of action Aminoglycosides bind to the 16S rRNA of the 30S subunit and inhibit protein synthesis. 1. Transport of aminoglycoside through cell wall and cytoplasmic membrane. a) Diffuse across cell wall of gram negative bacteria by porin channels. b) Transport across cell membrane by carrier mediated process liked with electron transport chain 2. Binding to ribosome resulting in inhibition of protein synthesis A.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Danmap 2006.Pmd
    DANMAP 2006 DANMAP 2006 DANMAP 2006 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark Statens Serum Institut Danish Veterinary and Food Administration Danish Medicines Agency National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark Editors: Hanne-Dorthe Emborg Danish Zoonosis Centre National Food Institute, Technical University of Denmark Mørkhøj Bygade 19 Contents DK - 2860 Søborg Anette M. Hammerum National Center for Antimicrobials and Contributors to the 2006 Infection Control DANMAP Report 4 Statens Serum Institut Artillerivej 5 DK - 2300 Copenhagen Introduction 6 DANMAP board: National Food Institute, Acknowledgements 6 Technical University of Denmark: Ole E. Heuer Frank Aarestrup List of abbreviations 7 National Veterinary Institute, Tecnical University of Denmark: Sammendrag 9 Flemming Bager Danish Veterinary and Food Administration: Summary 12 Justin C. Ajufo Annette Cleveland Nielsen Statens Serum Institut: Demographic data 15 Dominique L. Monnet Niels Frimodt-Møller Anette M. Hammerum Antimicrobial consumption 17 Danish Medicines Agency: Consumption in animals 17 Jan Poulsen Consumption in humans 24 Layout: Susanne Carlsson Danish Zoonosis Centre Resistance in zoonotic bacteria 33 Printing: Schultz Grafisk A/S DANMAP 2006 - September 2007 Salmonella 33 ISSN 1600-2032 Campylobacter 43 Text and tables may be cited and reprinted only with reference to this report. Resistance in indicator bacteria 47 Reprints can be ordered from: Enterococci 47 National Food Institute Escherichia coli 58 Danish Zoonosis Centre Tecnical University of Denmark Mørkhøj Bygade 19 DK - 2860 Søborg Resistance in bacteria from Phone: +45 7234 - 7084 diagnostic submissions 65 Fax: +45 7234 - 7028 E.
    [Show full text]
  • The Inhibition by Chloramphenicol of Nascent Protein Formation in E
    1224 BIOCHEMISTRY: WEBER AND DEMOSS PROC. N. A. S. 3Mitchell, P., Ann. Rev. Microbiol., 13, 407 (1959); Quart. J. Exptl. Physiol., 44, 207 (1959). 4Munkres, K. D., N. H. Giles, and M. E. Case, Arch. Biochem. Biophys., 109, 397 (1965). 5 Munkres, K. D., and F. M. Richards, Arch. Biochem. Biophys., 109, 457 (1965). 6 Ibid., p. 466. 7Munkres, K. D., Arch. Biochem. Biophys., 112, 340 (1965). 8 Munkres, K. D., Biochemistry, 4, 2180, 2186 (1965). 9 Munkres, K. D., unpublished data. 10 Luck, D. J. L., and E. R. Reich, these PROCEEDINGS, 52, 931 (1964). 11 Criddle, R. S., R. M. Bock, D. E. Green, and H. D. Tisdale, Biochemistry, 1, 827 (1962). 12Woodward, D. O., and K. D. Munkres, these PROCEEDINGS, 55, 872 (1966). 13 Chen, R. F., and R. L. Bowman, Science, 147, 729 (1965). 14 Munkres, M. M., and K. D. Munkres, manuscript in preparation. 16 Green, D. E., and D. M. Ziegler, in Methods in Enzymology, ed. S. P. Colowick and N. 0. Kaplan (New York: Academic Press, 1963), vol. 6, p. 113. 16 Fernindez-Mor6n, H., Circulation, 26, 1039 (1962); Blair, P. V., T. Oda, D. E. Green, and H. Fern6ndez-Mor6,n, Biochemistry, 2, 756 (1963). 17 Allmann, D. W., and E. Bachmann, Federation Proc., 24, 425 (1965). 18 Weber, G., Advan. Protein Chem., 8, 416 (1953). 19 Mitchell, P., in Membrane Transport and Metabolism (New York: Academic Press, 1961), p. 22. 20 Crick, F. H. C., and L. E. Orgel, J. Mol. Biol., 8, 161 (1964). 21 Reithel, F. J., Advan. Protein Chem., 18, 123 (1963).
    [Show full text]
  • Sabouraud Chloramphenicol Gentamicin Agar 56594 - 63774 Agar / Selective Medium for the Isolation of Fungi
    SABOURAUD CHLORAMPHENICOL GENTAMICIN AGAR 56594 - 63774 AGAR / SELECTIVE MEDIUM FOR THE ISOLATION OF FUNGI 1- INTENDED USE Sabouraud Chloramphenicol Gentamicin Agar is recommended for the isolation of all species of yeasts and filamentous fungi from biological specimens presenting mixed fungal and bacterial flora. 2- PRINCIPLE The growth of fungi is promoted by the nutrients provided by peptones and glucose. Gentamicin and chloramphenicol inhibit the growth of most bacteria such as Enterobacteriaceae, Pseudomonas, and Staphylococci. 3- HOW SUPPLIED • Ready to use medium: - box of 20 Petri dishes (90 mm) (SCG) code 63774 - 25 x 8 ml slant tubes code 56594 4- THEORETICAL COMPOSITION (g/l of distilled water) This agar is prepared according to the theoretical formula of medium C of the European Pharmacopoeia (1), with the addition of chloramphenicol and gentamicin. Peptone 10 Glucose 40 Agar 12 5- STORAGE • Medium in tubes: at +2-8°C. • Medium in Petri dishes: at +2-8°C. The expiry date and batch number are indicated on the packaging. 6- INSTRUCTIONS Material: • Material provided: Sabouraud Gentamicin Chloramphenicol agar. Inoculation: All biological specimens can be inoculated onto Sabouraud Gentamicin Chloramphenicol agar. Refer to current recommendations for storage of biological specimens (2). Incubation: The incubation temperature and incubation time vary according to the characteristics and the type of fungus examined. These parameters are determined by the user. Temperature: As a rule, the optimal temperature for the detection of fungi in biological specimens is 30-35°C. The incubation of several culture media at different temperatures (25-27°C, 30-35°C) may be justified when testing for particular fungal species.
    [Show full text]
  • Antibiotic Dispensing in Rural and Urban Pharmacies in Hanoi-Vietnam
    Antibiotic dispensing in rural and urban pharmacies in Hanoi-Vietnam Do Thi Thuy Nga Global Antibiotic Resistance Partnership-Vietnam Oxford University Clinical Research Unit Practical causes of antibiotic resistance n Development of resistance is often complicated and multi factorial n Important drivers: Ø Inappropriate use of antimicrobials in human medicine Ø Use in agriculture Community - important source of antibiotic use Hospitals Health stations Pharmacies in community 38,916 retail drug outlets* Source: Drug Administration, MoH in 2008 Objectives n To assess the current practices and economic profitability of antibiotic sales for rural and urban pharmacies in northern Vietnam Setting of study: Hanoi region Rural: Urban: Dong Bavi Da Districts District Time: July-September 2010 Sample size and sampling 2000 private pharmacies Exclude: - Pharmacies inside Hospital Random - Whole sale Pharmacies selection 30 private pharmacies Urban: Rural: -2 cases refused No refused cases -Selected 2 additional one 15 in urban 2 settings 15 in rural Data collection & analysis n Combine Quantitative and Qualitative methods §. In-pharmacy observation §. Record drug sales to every client §. Post-observation questionnaire In-depth interviews with drug sellers n Data analysis: MS Access, SPSS software Descriptive statistics as appropriate Markup of antibiotic = selling price – purchase price (wholesale price) Pharmacy profile GPP Urban Yes Rural No 0% 20% 40% 60% 80% 100% Owner’s degree Urban Elementary Pharm. Rural Assistant Pharm. Pharmacist 0% 20% 40% 60% 80% 100% Drug seller's degree Urban Elementary Pharm. Rural Assistant Pharm. Assistant Doctor 0% 20% 40% 60% 80% 100% Number of drug sellers Urban 1 Rural 2 3 0% 20% 40% 60% 80% 100% Frequent Using references Urban Sometimes Rural Rare Never 0% 20% 40% 60% 80% 100% Client profile 60.0 50.0 40.0 30.0 Female Male 20.0 10.0 0.0 <15 16-25 26-40 41-60 >60 Age Left: Urban Right: Rural Average number of customers/day/pharmacy 46 50 40 30 19 Client not buy Abs Client buy Abs 20 Nr.
    [Show full text]